For medical media useVeeva Z4-9228 | Date of preparation: February 2018 | Date of expiry: February 2020

Reference | 1. World Health Organization. Cardiovascular Disease Fact Sheet. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 28 February 2018.2. Joshi PH, Martin SS, et al. The Remnants of Residual Risk. J Am Coll Cardiol. 2015; 65(21): 2276-2278. 3. Laslett L, et al. “The Worldwide Environment ofCardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues: A Report From the American College of Cardiology.” J Am Coll Cardiol. 2012; 60 (25): S1-S49.4. Ojo A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Transactions of the American Clinical and ClimatologicalAssociation. 2014; 125: 229-246. 5. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation. 2017. 6. National

Institutes of Health. "Chronic Kidney Disease and Kidney Failure." Accessed 28 February 2018. https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=34. 7. The RALESInvestigators. Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (TheRandomized Aldactone Evaluation Study [RALES]). J Am Coll Cardiol. 1996; 78(8):902-907. 8. The National Kidney Foundation. Clinical Update on Hyperkalaemia. 2014.https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf. Accessed 28 February 2018.

More than 424.9 million adults worldwide have diabetes, with up to 628.6 million expected by 20455

An estimated 17.5 million people worldwide die from CVD in a year1

An estimated 200 million people worldwide have CKD4

With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors.

Metabolic

Cardio

RenalCVD is the leading cause of death in people with CKD and people with diabetes5,6

Hyperkalaemia occurs in up to 50% of patients with CKD and approximately 20% of patients with chronic heart failure (HF) taking mineralocorticoid receptor antagonists7,8

Overlapping disease statesThe growing unmet need in CVRM

Our distinctive approach to CVRM

Science is uncovering commonalities between CV, renal and metabolic disease, explaining why the idea of reducing CV risk is so complex.

Despite scientific advancements, cardiovascular disease (CVD) can cause high residual risk for recurrent cardiac events in certain patients and remains the #1 cause of death globally.1,2

From 2011 to 2025, the cumulative economic losses in low-income and middle-income countries from CVD are projected to be, close to US $3.76 trillion3

Type-2 diabetes is one of the top causes of CKD5

Rigorous Clinical Studies

We continue to strengthen our commitment to following the science through:

therapies and therapy combinations in our early to late-stage pipeline

60,000+ patients participating in Research & Development-led CV trials at 6,000+ sites worldwide

We are evaluating the use of our medicines in large patient populations in both established and emerging markets. These trials include ambitious global randomised clinical trials that are as close as possible to clinical practice, as well as transformational real-world evidence research.

Cardiovascular, Renal and Metabolism (CVRM)Our mission is to save patients’ lives by jointly addressing their cardio-renal-metabolic risks.

We are committed to delivering life-changing results for people living with CVRM, with medicines that have the potential to offer improved outcomes to hundreds of millions of patients across the globe.

Strategic Partnerships